Every decade of waiting costs remission in severe asthma

Design

multinational cohort study pooling three severe asthma registries and databases

Population

9,241 patients with severe asthma across 26 countries starting a biologic

Primary outcome

clinical remission 12 months after biologic initiation, with exacerbations, control and lung function

Effect

remission odds 0.86 (95% CI 0.84-0.88) per 10 years of prior asthma; 0.54 (0.30-0.98) per 10 g lifetime oral corticosteroid; 0.24 (0.21-0.28) with pre-biologic lung function impairment

Three registries were pooled - the International Severe Asthma Registry, the US CHRONICLE registry and the UK Optimum Patient Care Research Database, 26 countries and 9,241 patients in the association analyses - to ask whether the timing of biologic initiation, rather than the choice of biologic, affects what patients get from it.

Every proxy for delay pointed the same way. Odds of clinical remission at 12 months after starting a biologic fell to 0.86 (95% CI 0.84 to 0.88) for every 10 years of asthma beforehand, 0.78 (0.63 to 0.96) per decade of potential severe asthma, 0.24 (0.21 to 0.28) with pre-biologic lung function impairment, and 0.54 (0.30 to 0.98) for every 10 g of lifetime cumulative oral corticosteroid. Post-biologic exacerbation rates were 8% higher and lung function improvement 2.35% less for each decade of delay.

The authors' framing - move from reserving biologics to preserving lung function - is the right one, and it collides directly with how access works. Biologics are gated by prior failure almost everywhere, and in India by cost above all: for most patients the delay is not a clinical decision at all. That does not make the finding useless. It changes what should be documented while a patient waits, because cumulative steroid dose and declining lung function are the two variables that this study shows are being spent, and they are the two that make the eventual case for funding.

• Record cumulative oral corticosteroid dose in grams, not courses - it is a predictor and an argument
• Track FEV1 trajectory rather than single values while a patient waits for approval or funding
• Refer for biologic assessment at the point of eligibility, not after another year of failure
• Phenotype early - eosinophil count, IgE, FeNO where available - so no time is lost once funding exists
• Say plainly in referral letters what is being lost by the delay; that is what this evidence supports

Why it matters

It reframes the wait for a biologic as an active cost in lung function and steroid burden, rather than a neutral period of trying cheaper options first.

Don't overread it

This is registry association, not a randomised comparison of early against late initiation - it cannot prove that starting sooner causes remission.

The statistics, in plain English

These are associations from registry data, and the confounding runs in an awkward direction: patients who waited longer are also patients whose disease behaved differently, and some of the apparent cost of delay is really the cost of having harder disease. The odds ratio of 0.24 for lung function impairment is the clearest example - impaired lung function is both a consequence of delay and a marker of severity. What survives that caveat is the consistency: every proxy, across three registries and 26 countries, moved the same way.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.